We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Kohl Continues Investigation Into Avastin Availability

Kohl Continues Investigation Into Avastin Availability

November 30, 2007

Senate Special Committee on Aging Chairman Herb Kohl (D-Wis.) is continuing his investigation into Genentech’s decision to limit the availability of cancer drug Avastin, questioning company officials on their decision and asking the FDA’s opinion on the move.

Avastin (bevacizumab) is approved to treat colorectal cancer and lung cancer but commonly is used off-label to treat advanced age-related macular degeneration (AMD). Genentech’s Lucentis (ranibizumab) was approved last year to treat AMD. The drugs are closely related and share the same mechanism of action.

However, the price difference between the drugs is significant. Avastin has a wholesale acquisition cost of $550 for 100 mg while Lucentis’ is $1,950 for 0.5 mg. Because the Centers for Medicare & Medicaid Services is a big purchaser of Avastin, limiting the drug’s availability could cost taxpayers $1 billion to $3 billion a year, Kohl said.

In a letter to Genentech Product Development President Susan Desmond-Hellman, Kohl requested documents related to discussions Genentech had with sponsors of a forthcoming study comparing Lucentis and Avastin. While Desmond-Hellman said she was unaware any negotiations took place, other sources told committee staff such talks did occur. 

Kohl asked Desmond-Hellman to provide documentation regarding Genentech’s decision to send a letter to an unknown number of patients warning them against using Avastin off-label and explaining its possible side effects. He also requested notes from a July board meeting and internal company notes regarding limiting Avastin or the relative costs of Lucentis and Avastin, including correspondence with the FDA about Avastin inspections.

Finally, Kohl asked FDA Commissioner Andrew von Eschenbach for the agency’s official position on Avastin’s availability. While Genentech employees say the FDA is opposed to the company providing Avastin to compounding pharmacies, committee staff has learned the agency has not indicated that Genentech should limit its supply of Avastin to those pharmacies, Kohl said.

Kohl’s Nov. 16 letter to Desmond-Hellman can be seen at aging.senate.gov/letters/genentechltr.pdf, and his Nov. 14 letter to von Eschenbach can be seen at aging.senate.gov/letters/genentechfdaltr2.pdf.

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing